Current and projected future economic burden of Parkinson’s disease in the U.S.

= 4, 548) designed for this study. We estimated a U. S. prevalence of approximately one million individuals with diagnosed Parkinson's disease in 2017 and a total economic burden of 51. 9 billion. The total burden of PD includes direct medical costs of 25. 4 billion and 26. 5 billion in indirect and non-medical costs, including an indirect cost of 14. 2 billion (PWP and caregiver burden combined), non-medical costs of 7. 5 billion, and 4. 8 billion due to disability income received by PWPs. The Medicare program bears the largest share of excess medical costs, as most PD patients are over age 65. Projected PD prevalence will be more than 1. 6 million with projected total economic burden surpassing 79 billion by 2037. The economic burden of PD was previously underestimated. Our findings underscore the substantial burden of PD to society, payers, patients, and caregivers. Interventions to reduce PD incidence, delay disease progression, and alleviate symptom burden may reduce the future economic burden of PD.